Plasma Protein Therapeutics Market Report 2026

The plasma protein therapeutics market size has grown strongly in recent years. It will grow from $34.68 billion in 2025 to $37.09 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to increasing prevalence of primary immunodeficiency disorder, rising demand for immunoglobulin therapies, limited plasma donation infrastructure, advances in protein purification technologies, regulatory approvals for plasma-derived therapies.

The plasma protein therapeutics market size is expected to see strong growth in the next few years. It will grow to $48.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growth in recombinant albumin and coagulation factors, expansion of subcutaneous administration methods, increasing healthcare expenditure in emerging markets, technological advancements in precision medicine, rising public-private collaborations for plasma collection. Major trends in the forecast period include personalized plasma protein therapy development, expansion of recombinant protein production, increasing adoption of subcutaneous administration, growing awareness of rare blood disorders, enhanced supply chain and cold chain logistics.

The rising prevalence of autoimmune disorders is expected to drive the growth of the plasma protein therapeutics market in the coming years. Autoimmune disorders occur when the body's immune system mistakenly attacks and damages healthy cells. Therapeutic plasma exchange is used to treat these conditions, as it helps manage the production of autoantibodies that attack the body. For example, in May 2023, a study by the University of Glasgow, a UK-based public university, found that autoimmune disorders affect about 10% of the UK's population, surpassing previous estimates made in 2022. As a result, the increasing prevalence of autoimmune disorders is contributing to the growth of the plasma protein therapeutics market.

Leading companies in the plasma protein therapeutics market are focusing on developing innovative solutions, such as lyophilized plasma formulations, to meet the rising demand for portable, stable, and rapid-use blood products in emergency and pre-hospital care settings. Lyophilized plasma products are freeze-dried formulations that offer extended shelf life, easier storage, and quicker reconstitution compared to traditional frozen plasma. This makes them highly suitable for trauma, emergency medicine, and field environments. For instance, in October 2023, Octapharma AG, a Switzerland-based pharmaceutical company, received approval from European medical authorities for the lyophilized version of its octaplasLG product. This advanced formulation enables convenient pre-hospital transfusions, offering rapid availability, simplified handling, and enhanced stability for critical care situations. The product supports effective management of trauma and bleeding emergencies, reflecting Octapharma’s commitment to advancing patient care through innovative plasma-based therapies.

In June 2025, Grifols, a Spain-based provider of plasma-derived therapeutics, acquired Biotest AG for an undisclosed amount. This acquisition aimed to give Grifols full control over Biotest’s plasma-protein therapeutic portfolio, streamline operations, and strengthen its market position in the industry. Biotest AG, a Germany-based company, provides plasma-derived therapies such as immunoglobulins, coagulation factors, and specialty plasma proteins.

Major companies operating in the plasma protein therapeutics market are CSL Behring LLC, Grifols SA, China Biologic Products Holdings Inc., Takeda Pharmaceutical Company Limited, Baxter International Inc., Kedrion SpA, LFB SA, Emergent BioSolutions Inc., Reliance Life Sciences Private Limited, ADMA Biologics Inc., Prothya Biosolutions BV, Bio Products Laboratory Ltd., Biotest AG, Taibang Biological Group Co Ltd, Octapharma Plasma Inc., Green Cross Corporation, China National Biotec Group Company Limited, Kamada Ltd., Shire PLC, Octapharma AG.

North America was the largest region in the plasma protein therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasma protein therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plasma protein therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the plasma protein therapeutics market by increasing import costs of raw plasma and recombinant proteins, affecting overall production expenses. Segments such as immunoglobulin and coagulation factors, particularly in regions like Europe and Asia-Pacific, are most impacted due to reliance on imports. While tariffs have slowed supply chain operations, they have encouraged local plasma collection initiatives and domestic manufacturing expansion, providing opportunities for market growth and innovation in cost-effective production.

The plasma protein therapeutics market research report is one of a series of new reports that provides plasma protein therapeutics market statistics, including plasma protein therapeutics industry global market size, regional shares, competitors with a plasma protein therapeutics market share, detailed plasma protein therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the plasma protein therapeutics industry. This plasma protein therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plasma protein therapeutics refers to treatments derived from plasma and their recombinant analogs. These therapies are used to treat specific medical conditions by replacing missing or deficient proteins found in plasma, enabling recipients to lead healthier and more productive lives.

The main products in plasma protein therapeutics include immunoglobulin, albumin, coagulation factors, C1-esterase inhibitors, and other related products. Immunoglobulin is a component of blood plasma that contains immunoglobulins or antibodies. These therapies are administered through various routes, including intravenous and subcutaneous, and are used to treat a range of conditions such as primary immunodeficiency disorder (PID), idiopathic thrombocytopenic purpura, secondary immunodeficiency, hereditary angioedema, and other medical applications.

The plasma protein therapeutics market includes revenues earned by entities by providing therapy for liver disease and bleeding from trauma by using Alpha-1 Proteinase Inhibitors, Hyperimmune Globulins. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.